BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240305
DTEND;VALUE=DATE:20240308
DTSTAMP:20260515T233319
CREATED:20231017T095950Z
LAST-MODIFIED:20231017T095950Z
UID:37964-1709596800-1709855999@www.pharmajournalist.com
SUMMARY:DNA Process Development & Manufacturing Summit
DESCRIPTION:With the cell and gene therapy industry surging\, rapid advances in mRNA-based therapies\, and the advent of DNA vaccines\, the demand for quality DNA as a critical starting and therapeutic material has skyrocketed in recent years. \nThe DNA Process Development & Manufacturing Summit is the only industry-dedicated forum to focus on topics such as DNA construct design\, sequencing technology\, and scaling production for preclinical and clinical programs\, helping to expedited IND submissions and approvals. \nDownload the official event guide here: https://ter.li/9hpxb2 \nInnovative biopharma including BioNTech\, Genentech\, AskBio\, Pfizer\, Roche\, Sanofi and more will unite in Boston to build the ultimate roadmap from plasmids through to synthetic and novel DNA innovations\, helping you advance your manufacturing capabilities for high quality therapeutics and vaccines. \nRegister your place here: https://ter.li/8kdoo7
URL:http://www.pharmajournalist.com/event/dna-process-development-manufacturing-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240312
DTEND;VALUE=DATE:20240316
DTSTAMP:20260515T233319
CREATED:20231215T122622Z
LAST-MODIFIED:20231215T124912Z
UID:38363-1710201600-1710547199@www.pharmajournalist.com
SUMMARY:14th World ADC London 2024
DESCRIPTION:We find ourselves at the cutting edge of oncology innovation\, with the ADC field booming with excitement due to the constant eflux of clinical progress and a plethora of high-value collaborations. \nAs such the 14th World ADC London 2024 returns this March as a crucial touchpoint for all antibody drug conjugate developers across Europe. \nThis meeting is the place where innovation meets collaboration to drive antibody-drug conjugates forward and transform cancer therapy as we know it. Uniting 600+ industry experts and ADC newcomers\, this is a conversation you can’t afford to miss. \nTake a look at the full agenda here. \nEmbark on a knowledge-rich adventure as we explore the intricate nuances of ADC development. From the initial stages of target identification and antibody engineering to the complexities of clinical trials and CMC strategies to navigating commercialisation\, expect to leave this event with a comprehensive understanding of the entire ADC lifecycle. \nHere are some of the leading minds sharing translatable lessons to advance your pipeline including: \n\nAstrid Clarke\, Director\, Head of Early-Stage IND to Medicine Research\,Seagen\nColm Reddington\, Director- Global Regulatory\, Chemistry\, Manufacturing & Control\, AstraZeneca\nDaniel Milano\, Senior Director\, Process Development\, ImmunoGen\nDhiraj Gambhire\, Executive Director – Global Clinical Lead\, Enhertu\, Breast & Medical\, Daiichi Sankyo\nEmmett Scmidtt\, Vice President\, Lead External- Collaborations Project Team Global Clinical Development\, Merck & Co\nGerold Meindhart\, Vice President\, Asset & Portfolio Management\, Daiichi Sankyo\nIan Andrews\, Senior Manager\, Strategic External Development\, GlaxoSmithKline\nKurt Pike\, Senior Director\, External Innovation\, Janssen\nLarisa Stone\, Clinical Development Director\, Gilead\nLolke deHaan\, Vice President\, Toxicology\, ADC Therapeutics\nMike Liao\, Global Clinical Pharmacology Lead\, Genentech\nVenkatesh Pilla Reddy\, Senior Director\, Global PKPD & Pharmacometrics\, Eli Lilly\n\nSee the full speaker faculty and session details here. \nWhether you are pioneering ADC discoveries\, accelerating your conjugate through preclinical and clinical development\, or optimising your CMC efforts\, this is your chance to ahead of the curve with the high-quality and invaluable guidance of the supportive ADC community.
URL:http://www.pharmajournalist.com/event/14th-world-adc-london-2024/
LOCATION:ExCeL London\, Royal Victoria Dock\, 1 Western Gateway\, London\, E16 1XL\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:adc@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240318
DTEND;VALUE=DATE:20240321
DTSTAMP:20260515T233319
CREATED:20231123T125135Z
LAST-MODIFIED:20231123T125201Z
UID:38203-1710720000-1710979199@www.pharmajournalist.com
SUMMARY:7th Antigen-Specific Immune Tolerance Drug Development Summit
DESCRIPTION:Returning for the seventh year\, the 7th Antigen-Specific Immune Tolerance Summit (March 18 – 20\, 2024 | Boston\, MA) will lean into the industry’s key challenges from details of T-cell assays in preclinical and larger clinical studies; to pioneering CAR-Treg\, mRNA-LNP\, biologic\, peptide\, approaches and updates on proof-of-concept and ongoing clinical programs. This is the highest value meeting on the immune tolerance community’s conference calendar. \nThis is your comprehensive guide to define your pipeline and therapeutic development strategy for 2023\, delve into your opportunity to create tolerizing\, curative\, strategies for autoimmunity\, and tap into your tolerance strategy to tackle immunogenicity and transform the biologic landscape. Network with large pharma scouts\, industry super-giants\, and biotech pioneers to build meaningful partnerships and gather insights beyond the literature. \nExpect to be involved in interactive discussions on: \n\nTackle antigen-selection and deepen your understanding of the role of T-cells\, B-cells and T-regs in immune tolerance evaluate strategies and technologies in complex heterogenous disease settings with COUR Pharmaceuticals and Pfizer.\nBuild the biomarker toolbox and engage in discussions around the true markers of ‘tolerance’ for practical tolerance strategies and markers for determinants of efficacy\, patient selection\, and therapeutic durability with Takeda\, University of Pittsburgh\, Imcyse\, and Anokion\nAssess toxicity and durability of tolerance therapeutics using preclinical models to inform the frequency of administration and the persistence or loss of tolerance over time with Toleranzia and University of Helsinki\nEvaluate delivery technologies and novel approaches including CAR-Treg\, mRNA-LNP\, biologics\, and more to propel tolerizing therapies through proof-of-concept to the clinic with Sonoma\, Moderna\, and Integrated Nanotherapeutics\nHarness mechanistic models and autoimmune disease models to highlight efficacious tolerance induction across diseases including Celiac\, Type 1 Diabetes\, Multiple Sclerosis\, Rheumatoid Arthritis\, and more with GRO Bioscience\, RheumaGen\, NexImmune\, and Parvus Therapeutics\n\nJoin 110+ autoimmune and immunologist scientists\, corporate strategists\, and large pharma scouts at this timely and comprehensive summit set to unite the immune tolerance field. From innovative\, start-up biotechs to big pharma super giants\, this is your unique opportunity to discuss advancing efficacious antigen- and drug-specific tolerance approaches to patients in need. \nDownload the full agenda here to see our full speaker faculty\, 3-day agenda and audience breakdown: https://ter.li/7teig8
URL:http://www.pharmajournalist.com/event/7th-antigen-specific-immune-tolerance-drug-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240318
DTEND;VALUE=DATE:20240321
DTSTAMP:20260515T233319
CREATED:20240213T100720Z
LAST-MODIFIED:20240213T100720Z
UID:38674-1710720000-1710979199@www.pharmajournalist.com
SUMMARY:9th Innate Killer Summit 2024
DESCRIPTION:“The translational impact and nature of the work that was being presented were outstanding. You get a lot of insights from your peers regarding their experience interacting with the regulatory agencies” – ONK Tx \nThe 9th Innate Killer Summit is designed for experts striving to realize the clinical potential of NK–based therapies from early discovery to later stages in the clinic through 3 dedicated tracks of content: Pre-clinical\, Clinical Translation\, CMC & Process Development. \nSpecifically focussing on advancing NK engager\, bispecific\, cell therapy\, and combination therapy approaches to improve the clinical durability and streamlining manufacturing. Come together with industry experts to brainstorm best approaches to enhance efficacy and persistence as well as reduce the cost of production. \nCollaborating closely with pioneers such as Dan Kaufman\, Evren Alici\, and industry experts from Zelluna Immunotherapy\, Artiva Biotherapeutics\, Affimed\, Sanofi\, Immunity Bio\, Cytovia (to name a few!) to ensure the critical priorities of the field are captured. Join to gain practical takeaways for novel techniques in engineering NK cells while preserving cell fitness\, best practice clinical trial design methods\, benefits of feeder-free cell expansion and many more! \nRanging from a jam-packed pre-conference workshop day with 6 different workshops and a bootcamp ranging from preclinical to CMC and process development. Also up for offer are 10+ plenary talks across the main conference days where experts will guide you through the current cell therapy landscape\, an industry leaders annual briefing\, a range of clinical data presentations\, and an investors panel!
URL:http://www.pharmajournalist.com/event/9th-innate-killer-summit-2024/
LOCATION:San Diego Marriott Del Mar\, 11966 El Camino Real\, San Diego\, CA\, 92130\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240319
DTEND;VALUE=DATE:20240322
DTSTAMP:20260515T233319
CREATED:20231108T095535Z
LAST-MODIFIED:20231109T143458Z
UID:38106-1710806400-1711065599@www.pharmajournalist.com
SUMMARY:6th CKD Drug Development Summit
DESCRIPTION:The Definitive Industry Forum for CKD Drug Development \nAdvance More Personalized Therapies for Rare & Common Kidney Diseases \nThe 6th CKD Drug Development Summit is the definitive forum for KOLs\, industry experts\, and regulators to bring kidney innovation onto the next generation of drug development\, uniting 200+ biopharma stakeholders\, from scientific research to clinical development and outcomes\, across three days of concentrated discussion. \nFrom uncovering the genetic architecture of specific CKD subgroups and revolutionizing translatable models of renal pathophysiology\, to breaking new ground in CKD trial design and implementing new therapies into the treatment paradigm\, join Novo Nordisk\, Boehringer Ingelheim\, Eli Lilly\, AstraZeneca\, the FDA\, Regeneron\, Novartis and more to collaborate and drive progress of precision medicine and reinvent the landscape of rare and common kidney disease treatments.
URL:http://www.pharmajournalist.com/event/6th-ckd-drug-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240319
DTEND;VALUE=DATE:20240322
DTSTAMP:20260515T233319
CREATED:20231116T104232Z
LAST-MODIFIED:20231116T104232Z
UID:38153-1710806400-1711065599@www.pharmajournalist.com
SUMMARY:3rd Cell Therapy Potency Assay Summit
DESCRIPTION:In the dynamic cell therapy landscape\, the challenge of potency assay development looms large\, as exemplified by clinical holds experienced by Mesoblast and Verve Therapeutics in recent years. \nAt the 3rd Cell Therapy Potency Assay Summit\, we bring together over 120 analytical\, quality control\, and regulatory experts including esteemed organizations like BMS\, J&J\, Atara Biotherapeutics\, Fate Therapeutics\, Health Canada. The summit will address these pressing concerns with the goal to collaboratively design more effective potency assays that not only streamline regulatory approval but also reduce hold times significantly. \nJoin us and leave equipped with industry insights that enable you to develop practical and reproducible assays\, providing a deeper understanding of your cell therapy products. \nFind out more here: https://ter.li/e448ls
URL:http://www.pharmajournalist.com/event/3rd-cell-therapy-potency-assay-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240319
DTEND;VALUE=DATE:20240322
DTSTAMP:20260515T233319
CREATED:20231207T113944Z
LAST-MODIFIED:20231207T113944Z
UID:38292-1710806400-1711065599@www.pharmajournalist.com
SUMMARY:4th Operationalize Expanded Access Programs Summit
DESCRIPTION:Following the increasing interest in access to investigational medicines from patients\, the harmonization of guidance and research on the value of expanded access programs witnesses a critical rise. \nBack in Boston as the only industry forum defining global regulations for EAP and your definitive networking opportunity to connect with managed access teams from other leading and new companies that are immersing themselves in this evolving field of opportunity and life-changing support. \nReunite with 120+ industry experts setting up and leading EAPs at the 4th Operationalize Expanded Access Programs Summit and gain practical take aways on how to construct a reliable system\, define a clear exit strategy\, understand updated local and global regulations\, and determine the role of real-world data to optimize the operationalization of your EAP. This is your one-stop shop to capturing industry’s latest case studies in setting up a program globally\, reaching physicians and patients\, collecting real-world data\, and maximizing vendor selection to improve the operationalization of EAP and streamline access to life-changing therapies. \nWhat’s New for 2024? \n\nA deep dive into the country-level challenges and regulators’ requirements along with the best practices for labelling\, shipping\, and reporting to deliver a successful project across the US\, LATAM and Middle East with UCB\, GSK\, Novartis\, Biogen\, Sanofi\, SpringWorks Therapeutics and Day One Biopharmaceuticals\nA delve into the experiences and perspectives of physicians to better understand their pain points and how they become aware of EAPs to strengthen these relationships and move the field forward with the University of Michigan and Riboscience\nAn active discussion into the role of real-world data and the setup of an EAP through value-based organisations to obtain a large community of patients and carry this out with ease with AstraZeneca\n\nDon’t miss out on your opportunity to be amongst physicians\, patients and passionate EAP and clinical supply experts from Novartis\, Daiichi Sankyo\, GSK\, AstraZeneca\, Gilead\, Biogen\, Sanofi\, Eli Lilly\, Regeneron\, and many more to discover novel strategies in overcoming operational hurdles and deliver life-saving treatments to patients more efficiently. \nTo know more visit: https://operationalize-eap.com/
URL:http://www.pharmajournalist.com/event/4th-operationalize-expanded-access-programs-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240319
DTEND;VALUE=DATE:20240322
DTSTAMP:20260515T233319
CREATED:20231207T114720Z
LAST-MODIFIED:20231207T114720Z
UID:38297-1710806400-1711065599@www.pharmajournalist.com
SUMMARY:4th Wet AMD & Diabetic Eye Disease Drug Development Summit
DESCRIPTION:The 4ᵗʰ Wet AMD & Diabetic Eye Disease Drug Development Summit is returning to Boston this upcoming March to unite 70+ industry-based retinal vascular experts from the likes of Bayer\, Boehringer Ingelheim\, Genentech\, Novartis and OcuTerra\, at the only industry-dedicated forum to transform the potential of treatment of chronic\, sight-threatening retinal vascular diseases to improve patient outcomes. \n \nNew additions for 2024 include: \n\nFresh perspectives from the new companies speaking at the 2024 meeting including Aviceda Therapeutics\, Bayer\, Boehringer Ingelheim\, OcuTerra\, Novartis\, Genentech\, and Adverum Biotechnologies\n16+ brand-new speakers out of the 18+ speaker faculty consisting of industry experts and academic leaders working on preclinical models\, choroidal neovascularization\, retinal inflammation\, durable drug delivery to the retinal vascular system and more\nRobust new content focusing on industry-specific topics such as new targets\, in vivo and in vitro models\, retinal imaging and clinical biomarkers and new modalities for retinal and choroidal neovascularization\n\nTo know more visit: https://ter.li/cjnu7k
URL:http://www.pharmajournalist.com/event/4th-wet-amd-diabetic-eye-disease-drug-development-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240319
DTEND;VALUE=DATE:20240322
DTSTAMP:20260515T233319
CREATED:20231207T115623Z
LAST-MODIFIED:20231207T115623Z
UID:38307-1710806400-1711065599@www.pharmajournalist.com
SUMMARY:2nd Targeted Intracellular Delivery Summit
DESCRIPTION:Step into the 2nd Targeted Intracellular Delivery Summit\, a thrilling exploration of cutting-edge advancements in drug delivery. This year\, we redefine possibilities\, venturing beyond traditional boundaries with a focus on cellular biology and intracellular mechanisms. \nOptimize drug delivery\, overcome endosomal challenges\, and expand therapies beyond the liver with in-depth case studies and a Pre-Conference Workshop Day. Gain insights into targeted cell interventions for cancer and autoimmune diseases\, re-thinking innovative delivery platforms and strategies for cargo delivery into novel targets. \nEngage in transformative discussions and exclusive case studies with industry giants like Sanofi\, Merck & Co\, Sana Biotechnology\, and Capstan Therapeutics. Uniting C-Level Executives\, Researchers\, and Directors\, this event is the only industry-led forum focused on cellular mechanisms to enable targeted intracellular drug delivery. Addressing challenges in compartmentalization and endosomal escape\, it aims to optimize therapeutic efficacy and minimize toxicity. \nJoin us in March 2024 to delve into the forefront of intracellular targeting\, where innovation meets expertise to propel your drug pipelines toward unprecedented success. \nTo know more visit: https://ter.li/p72w9g
URL:http://www.pharmajournalist.com/event/2nd-targeted-intracellular-delivery-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240325
DTEND;VALUE=DATE:20240328
DTSTAMP:20260515T233319
CREATED:20231115T103534Z
LAST-MODIFIED:20231115T103534Z
UID:38132-1711324800-1711583999@www.pharmajournalist.com
SUMMARY:6th Neuroimmunology Drug Development Summit
DESCRIPTION:Neuroimmunology targets in neurodegeneration are hotter than ever. Capturing biopharma’s latest research spanning discovery to early clinical development\, the 6th Neuroimmunology Drug Development Summit is the industry-choice\, comprehensive forum dedicated to translating neuroinflammatory-targeted therapeutics into clinical trials. \nWhat are the top features to look forward to in 2024? \n\nDoubled pre-conference workshop content\, with 6 deep-dive sessions tailored to your discovery biology and translational expertise led by neuroimmunology leaders from Lundbeck\, Sanofi\, Merck\, Regeneron\, and more\nAgenda content spotlighted neurodegeneration – including TREM2 clinical data updates and breaking down trial design and rationale with Alector and Vigil Neuroscience\nNew case studies beyond microglia\, with sessions spearheading astrocyte function and therapeutic intervention from Sanofi\, IMNEWRUN\, and UCL\nBrand-new content on immunocompetent brain organoids to recapitulate and investigate complex neuroimmune interactions with Roche and Herophilus\nIt is the biggest and most comprehensive program to date\, with 38+ industry and academic speakers\, including new presenting companies Eisai\, EMD Serono\, Ventus Therapeutics\, PTC Therapeutics\, and Inflammasome Therapeutics\n\nUniting 100+ all-star leaders across industry and academia\, this is the must-attend forum for anyone working on treatments targeting neuroinflammation across neurological indications and looking to accelerate their candidates into the clinic in 2024. \nTo know more visit: https://ter.li/wb3bhh
URL:http://www.pharmajournalist.com/event/6th-neuroimmunology-drug-development-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240325
DTEND;VALUE=DATE:20240328
DTSTAMP:20260515T233319
CREATED:20231120T150249Z
LAST-MODIFIED:20231120T150249Z
UID:38186-1711324800-1711583999@www.pharmajournalist.com
SUMMARY:5th Supply Chain & Logistics for Cell Therapies Summit
DESCRIPTION:As the cell therapy field rapidly expands\, keeping ahead of the race by creating a visible and robust supply chain has never been more critical to ensure you have the skills and strategy to develop into the next stage of your pipeline. \nJoin us at the 5th Supply Chain & Logistics for Cell Therapies Summit in Boston from March 25-27th. This summit will bring together logistics and clinical operations experts to establish standardized best practices in planning\, communication and assist companies in scaling up to consistently deliver cell therapies safely\, on time\, and in a cost-effective process. \nSeize the opportunity to enhance your expertise in cell therapy logistics by connecting with leaders in clinical operations\, including esteemed companies like Beam Therapeutics\, Lovance\, Arcellx\, Jassen Pharmaceuticals\, and more. \nDownload the event guide to learn more: https://ter.li/d6jto3
URL:http://www.pharmajournalist.com/event/5th-supply-chain-logistics-for-cell-therapies-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240326
DTEND;VALUE=DATE:20240329
DTSTAMP:20260515T233319
CREATED:20231107T111306Z
LAST-MODIFIED:20231107T111306Z
UID:38097-1711411200-1711670399@www.pharmajournalist.com
SUMMARY:5th Glioblastoma Drug Development Summit
DESCRIPTION:The 5th Glioblastoma Drug Development Summit is the only industry led forum for large pharma\, biotech\, neuro-oncologists and academic KOLs to unite alongside a dedicated panel of investors under the common goal to breakthrough GBM barriers to accelerate the practical translation and clinical development of emerging therapeutics for glioblastoma and CNS tumor patients. \nDiscover innovative approaches to surpassing the blood-brain barrier to unlock previously uncovered therapeutic potential\, keep ahead of the latest clinical trial design rationale and navigate the regulatory landscape for novel combination therapies with actionable insights to improve clinical success. \nWith promising clinical readouts from a range of therapeutic modalities\, novel drug targets emerging and positive advances in state-of-the-art technologies like sonodynamic therapy\, there is more potential than ever before to be unlocked within the GBM space. \nTo elevate your current standards\, join this unique collaboration between industry giants such as Novartis\, pioneering biotechs such as Day One Biopharmaceuticals\, world-renowned academics and investors. Embrace positive clinical outcomes alongside a dedicated community committed to defeating GBM/CNS tumors and transforming lives. \nAccess the complete agenda here including a packed pre-workshop conference day\, panel discussions\, poster sessions and important networking opportunities.
URL:http://www.pharmajournalist.com/event/5th-glioblastoma-drug-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240326
DTEND;VALUE=DATE:20240328
DTSTAMP:20260515T233319
CREATED:20231201T114649Z
LAST-MODIFIED:20231201T143620Z
UID:38253-1711411200-1711583999@www.pharmajournalist.com
SUMMARY:Pharma USA 2024
DESCRIPTION:Accelerate patient value. Pioneer healthcare’s transformation.  \nHealthcare reforms are finally paving the way to affordable access to medicines\, yet this progress threatens the development of future life-saving therapies. The moment is now to prove ourselves as a trusted industry ally and the ultimate safe harbor for patients. \nThe key? Delivering aligned value to HCPs\, patients\, payers and regulators. \nSpeed and scale is non-negotiable. Those afraid to accelerate will be left behind. We must adapt to evolving payer needs\, empower HCPs with crucial insights\, bridge regulatory gaps and co-create with patients. Only then will we achieve exceptional outcomes. \nReuters Events: Pharma USA 2024 is where senior pharma executives from Commercial\, Marketing\, Medical Affairs\, RWE\, Market Access\, Patient Engagement\, as well as key stakeholders\, will come together to map out how they can deliver value to overcome the challenges that are hindering scientific innovation. \nJoin over 1\,200 of North America’s pharma pioneers\, leading solutions provider\, and patient advocates to sharpen short-term strategy and unite for a long-term future to exceed stakeholder desires across the value chain. \nTo know more visit: https://bit.ly/3GpdsrU
URL:http://www.pharmajournalist.com/event/pharma-usa-2024/
LOCATION:Pennsylvania Convention Center\, 1101 Arch Street\, Philadelphia\, PA\, 19107\, United States
ORGANIZER;CN="Reuters Events":MAILTO:Kana.Hutton@thomsonreuters.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240326
DTEND;VALUE=DATE:20240330
DTSTAMP:20260515T233319
CREATED:20240103T114154Z
LAST-MODIFIED:20240103T114154Z
UID:38420-1711411200-1711756799@www.pharmajournalist.com
SUMMARY:7th Gene Therapy for Rare Disorders Summit
DESCRIPTION:This past year has seen more gene therapies approved by the FDA than the previous five years combined\, and almost triple the number of clinical trials in gene therapy have been initiated in H1 of 2023 compared to the same time frame in the previous year. \nTo maximize the value of your late-stage gene therapy assets\, the 7th Gene Therapy for Rare Disorders Summit is returning to tackle head-on the significant clinical\, manufacturing\, regulatory\, and commercial challenges facing gene therapy programs today. \nBringing together key figures from industry\, regulatory bodies\, patient non-profits\, payers\, and key service providers\, this is the field’s foremost meeting for collectively progressing rare gene therapy programs into and through the clinic. \nJoin us to leverage essential insights from over 300 peers from leading biopharma companies with direct experience in driving gene therapies through the clinic and into the market. Keep your finger on the pulse\, form connections with top decision-makers\, and address your specific clinical\, manufacturing\, regulatory\, and commercial bottlenecks to safeguard against costly delays and progress your gene therapies through the pipeline quickly and safely. \nTo know more visit: https://ter.li/x4qqur
URL:http://www.pharmajournalist.com/event/7th-gene-therapy-for-rare-disorders-summit/
LOCATION:The Westin Copley Place\, 10 Huntington Avenue\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR